Trial Profile
Solifenacin Succinate in a Flexible Dose Regimen With Simplified Bladder Training Versus Solifenacin Succinate in a Flexible Dose Regimen Alone in a Prospective, Randomized, Parallel Group, Overactive Bladder Symptom Study
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 24 Dec 2021
Price :
$35
*
At a glance
- Drugs Solifenacin (Primary)
- Indications Overactive bladder
- Focus Therapeutic Use
- Acronyms SOLAR
- Sponsors Astellas Pharma
- 28 Nov 2008 New trial record.
- 24 Oct 2008 Results reported at the 38th International Continence Society meeting 2008.